POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes

Affiliations

¹ Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: tobias.tritschler@insel.ch.
² Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
³ Division of Pulmonary, Critical Care, and Sleep Medicine, New York University Langone Health System, New York, NY.

Editorial

Tobias Tritschler et al. Chest. 2022 Jun.

. 2022 Jun;161(6):1446-1448.

doi: 10.1016/j.chest.2022.01.036. Epub 2022 Mar 15.

¹ Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: tobias.tritschler@insel.ch.
² Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
³ Division of Pulmonary, Critical Care, and Sleep Medicine, New York University Langone Health System, New York, NY.

No abstract available

Comment in

Rebuttal From Dr David Jimenez et al.
Jimenez D, Rali P, Doerschug K. Jimenez D, et al. Chest. 2022 Jun;161(6):1453-1455. doi: 10.1016/j.chest.2022.01.038. Epub 2022 Mar 15. Chest. 2022. PMID: 35469672 Free PMC article. No abstract available.
COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No.
Jimenez D, Rali P, Doerschug K. Jimenez D, et al. Chest. 2022 Jun;161(6):1448-1451. doi: 10.1016/j.chest.2022.01.037. Epub 2022 Mar 15. Chest. 2022. PMID: 35550714 Free PMC article. No abstract available.

1. Leentjens J., van Haaps T.F., Wessels P.F., Schutgens R.E.G., Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524–e533. - PMC - PubMed
1. Lawler P.R., Goligher E.C., Berger J.S., et al. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802. - PMC - PubMed
1. Sholzberg M., Tang G.H., Rahhal H., et al. RAPID trial investigators Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. - PMC - PubMed
1. Spyropoulos A.C., Goldin M., Giannis D., et al. HEP-COVID Investigators Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–1620. - PMC - PubMed
1. Goligher E.C., Bradbury C.A., McVerry B.J., et al. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–789. - PMC - PubMed